Delivery Order SPE2DB22D9239-SPE2DB25FDL35
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $37,137.60 by the Defense Logistics Agency (DLA) on August 21, 2025. The delivery order, which carries no set-aside designation, is for Xolair 150 mg/ml syringes with an ultimate completion date of September 12, 2025. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite...
- The U.S. Defense Logistics Agency Medical Supply Chain issued a firm fixed-price delivery order valued at $1,712.22 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml. The award was made on July 30, 2025, with an ultimate completion date of August 13, 2025, and will be performed at the vendor's location in Park Ridge, Illinois. This delivery order carries no set-aside designation and represents a discrete purchase under DMS Pharmaceutical Group's larger indefinite delivery...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,737 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Xolair 75 mg/0.5 ml syringe 0.5 ml, with an ultimate completion date of October 30, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) awarded to DMS Pharmaceutical Group Inc. under the DLA's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency's Medical Supply Chain for the supply of Xolair 150 mg/ml syringes. The award, issued on August 29, 2025, with an ultimate completion date of September 22, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 14, 2025, for the supply of Xolair 300 mg/2 mL syringes. The contract is valued at $3,720.96 and is structured as a firm fixed-price delivery order with an ultimate completion date of September 5, 2025. This award was made without a set-aside designation, allowing the vendor to compete on the open...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $2,321.10 by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract, awarded without set-aside designation, carries a firm fixed-price structure with an ultimate completion date of September 18, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, valued at $1,547.40 with an ultimate completion date of September 10, 2025, was issued without set-aside designation. DMS Pharmaceutical Group competes effectively in federal procurement leveraging its small business status and established...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,273.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL auto-injector units. The delivery order, awarded on August 15, 2025, with an ultimate completion date of September 8, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $9,284.40 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order with an ultimate completion date of September 15, 2025. This delivery order was issued without a set-aside designation and represents a single-line procurement under DLA's existing...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 300 mg/2 ml auto-injector prefilled syringes. The contract, valued at $6,848.92 with a firm fixed-price structure, was awarded on August 13, 2025, with an ultimate completion date of September 4, 2025. This delivery order carries no set-aside designation and will be performed at the company's Park...
- SPE2DB22D9239Indefinite Delivery Contract
- SPE2DB22D9239-SPE2DB25FDL35Delivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its location in Park Ridge, IL. This delivery order was issued without a set-aside designation and carries an ultimate completion date of September 16, 2025. The award represents a continuation of DMS Pharmaceutical Group's substantial role within the federal pharmaceutical supply chain, leveraging its existing indefinite delivery contract with DLA. This delivery order falls under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract (IDC) with the DLA valued at approximately $500 million and valid through November 2026. The parent IDC, established under the SPE2DB program, enables the agency to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. Xolair (omalizumab) is a monoclonal antibody used to treat moderate-to-severe allergic asthma and other allergic conditions, making this delivery order part of DLA's ongoing efforts to maintain adequate pharmaceutical inventories for military health facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.7k | 8/25/25 |